XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.21.2

Restructuring, Impairment, and Related Charges (Tables) | 3 Months Ended
--- | ---
Jun. 30, 2021
Restructuring and Related Activities [Abstract] |
Restructuring, Impairment, and Related Costs | Restructuring, impairment, and related charges during the three months ended June 30, 2021 consisted of the following:
| Three Months Ended June 30, 2021
(In millions) | U.S. Pharmaceutical (1) |  | Prescription Technology Solutions (1) |  | Medical-Surgical Solutions (1) |  | International (2) |  | Corporate (1) |  | Total
Severance and employee-related costs, net | $ | 2 |  |  | $ | — |  |  | $ | — |  |  | $ | 12 |  |  | $ | — |  |  | $ | 14 |
Exit and other-related costs (3) | 2 |  |  | 1 |  |  | 2 |  |  | 14 |  |  | 21 |  |  | 40 |
Asset impairments and accelerated depreciation | 8 |  |  | 17 |  |  | 4 |  |  | 34 |  |  | 41 |  |  | 104 |
Total | $ | 12 |  |  | $ | 18 |  |  | $ | 6 |  |  | $ | 60 |  |  | $ | 62 |  |  | $ | 158 |
(1)Costs primarily relate to the transition to the partial remote work model described above. (2)Primarily represents costs related to the transition to the partial remote work model and U.K. operating model and cost optimization efforts described above, as well as costs for optimization programs in Canada. (3)Exit and other-related costs primarily consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges during the three months ended June 30, 2020 consisted of the following:
| Three Months Ended June 30, 2020
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International (1) |  | Corporate (2) |  | Total
Severance and employee-related costs, net | $ | 1 |  |  | $ | — |  |  | $ | — |  |  | $ | 17 |  |  | $ | 20 |  |  | $ | 38 |
Exit and other-related costs (3) | 1 |  |  | — |  |  | 3 |  |  | 2 |  |  | 7 |  |  | 13 |
Asset impairments and accelerated depreciation | — |  |  | — |  |  | — |  |  | 4 |  |  | 1 |  |  | 5 |
Total | $ | 2 |  |  | $ | — |  |  | $ | 3 |  |  | $ | 23 |  |  | $ | 28 |  |  | $ | 56 |
(1)Primarily represents costs associated with the U.K. operating model and cost optimization efforts described above, and an operating model and cost optimization initiative which was substantially completed in the year ended March 31, 2021. (2)Primarily represents costs associated with an operating model and cost optimization initiative which was substantially completed in the year ended March 31, 2021. (3)Exit and other-related costs primarily include project consulting fees.
Schedule of Restructuring and Asset Impairment Charges | The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the three months ended June 30, 2021:
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Balance, March 31, 2021 (1) | $ | 19 |  |  | $ | 4 |  |  | $ | 3 |  |  | $ | 66 |  |  | $ | 59 |  |  | $ | 151 |
Restructuring, impairment, and related charges | 12 |  |  | 18 |  |  | 6 |  |  | 60 |  |  | 62 |  |  | 158 |
Non-cash charges | (8) |  |  | (17) |  |  | (4) |  |  | (34) |  |  | (41) |  |  | (104) |
Cash payments | (5) |  |  | (1) |  |  | (2) |  |  | (5) |  |  | (8) |  |  | (21) |
Other | — |  |  | — |  |  | (1) |  |  | (3) |  |  | (3) |  |  | (7) |
Balance, June 30, 2021 (2) | $ | 18 |  |  | $ | 4 |  |  | $ | 2 |  |  | $ | 84 |  |  | $ | 69 |  |  | $ | 177 |
(1)As of March 31, 2021, the total reserve balance was $151 million, of which $99 million was recorded in “Other accrued liabilities” and $52 million was recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheet. (2)As of June 30, 2021, the total reserve balance was $177 million, of which $127 million was recorded in “Other accrued liabilities” and $50 million was recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheet.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 5.P.3) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.P.4) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(b)(2)) -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 + Details
Name: | us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration